Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.

Phioanh Leia Nghiemphu Jeremie Vitte Eva Dombi Thien Nguyen Naveed Wagle Akira Ishiyama Ali R Sepahdari David Cachia Brigitte C WidemannDerald E BrackmannJoni K Doherty Michel Kalamarides Marco Giovannini

Published in: Journal of neuro-oncology (2024)

Volumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011).

Keyphrases

high resolution
signaling pathway
end stage renal disease
multiple sclerosis
oxidative stress
newly diagnosed
ejection fraction
chronic kidney disease
pi k akt
immune response
photodynamic therapy
patient reported outcomes
brain injury
blood brain barrier
cerebral ischemia